Canlyniadau Chwilio - Youngchul Song

  • Dangos 1 - 18 canlyniadau o 18
Mireinio'r Canlyniadau
  1. 1
    Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

    Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition gan Ryohei Katayama, Aki Aoyama, Takao Yamori, Jie Qi, Tomoko Oh‐hara, Youngchul Song, Jeffrey A. Engelman, Naoya Fujita

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

    MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors gan Alexa B. Turke, Youngchul Song, Carlotta Costa, Rebecca S. Cook, Carlos L. Arteaga, John M. Asara, Jeffrey A. Engelman

    Cyhoeddwyd 2012
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2

    Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2 gan Brent N. Rexer, Ritwik Ghosh, Archana Narasanna, Mónica V. Estrada, Anindita Chakrabarty, Youngchul Song, Jeffrey A. Engelman, Carlos L. Arteaga

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

    Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins gan Marta Guix, Anthony C. Faber, Shizhen Emily Wang, Maria G. Olivares, Youngchul Song, Sherman Qu, Cammie Rinehart, Brenda Seidel, Douglas Yee, Carlos L. Arteaga, Jeffrey A. Engelman

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

    PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 gan Hiromichi Ebi, Carlotta Costa, Anthony C. Faber, Madhuri Nishtala, Hiroshi Kotani, Dejan Juric, Patricia Della Pelle, Youngchul Song, Seiji Yano, Mari Mino‐Kenudson, Cyril H. Benes, Jeffrey A. Engelman

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

    Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers gan Hiromichi Ebi, Ryan B. Corcoran, Anurag Singh, Zhao Chen, Youngchul Song, Eugene Lifshits, David P. Ryan, Jeffrey A. Meyerhardt, Cyril H. Benes, Jeffrey Settleman, Kwok‐Kin Wong, Lewis C. Cantley, Jeffrey A. Engelman

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

    An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation gan Birgit Schoeberl, Anthony C. Faber, Danan Li, Mei‐Chih Liang, Katherine Crosby, Matthew Onsum, Olga Burenkova, Emily Pace, Zandra E. Walton, Lin Nie, Aaron Fulgham, Youngchul Song, Ulrik B. Nielsen, Jeffrey A. Engelman, Kwok‐Kin Wong

    Cyhoeddwyd 2010
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Combined targeting of HER2 and VEGFR2 for effective treatment of<i>HER2</i>-amplified breast cancer brain metastases

    Combined targeting of HER2 and VEGFR2 for effective treatment of<i>HER2</i>-amplified breast cancer brain metastases gan David P. Kodack, Euiheon Chung, Hiroshi Yamashita, João Incio, Annique M. Duyverman, Youngchul Song, Christian T. Farrar, Yuhui Huang, Eleanor I Ager, Walid S. Kamoun, Shom Goel, Matija Snuderl, Alisha Lussiez, Lotte Hiddingh, Sidra Mahmood, Bakhos A. Tannous, April F. Eichler, Dai Fukumura, Jeffrey A. Engelman, Rakesh K. Jain

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

    Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients gan Andrew P. Garner, Joseph M. Gozgit, Rana Anjum, Sadanand Vodala, Alexa B. Schrock, Tianjun Zhou, César Serrano, Grant Eilers, Mei‐Jun Zhu, Julia Ketzer, Scott Wardwell, Yaoyu Ning, Youngchul Song, Anna Kohlmann, Frank Wang, Tim Clackson, Michael C. Heinrich, Jonathan A. Fletcher, Sebastian Bauer, Victor M. Rivera

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    <i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

    <i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling gan Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, Christopher-Michael Gale, Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne

    Cyhoeddwyd 2007
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

    Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers gan Jeffrey A. Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R. Guimarães, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A. Perera, Youngchul Song, Lucian R. Chirieac, Ramneet Kaur, Angela Lightbown, Jessica Simendinger, Timothy Li, Robert F. Padera, Carlos Garcı́a-Echeverrı́a, Ralph Weissleder, Umar Mahmood, Lewis C. Cantley, Kwok‐Kin Wong

    Cyhoeddwyd 2008
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

    Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC gan Alexa B. Turke, Kreshnik Zejnullahu, Yi‐Long Wu, Youngchul Song, Dora Dias‐Santagata, Eugene Lifshits, Luca Toschi, Andrew M. Rogers, Tony Mok, Lecia V. Sequist, Neal I. Lindeman, Carly Murphy, Sara Akhavanfard, Beow Y. Yeap, Yun Xiao, Marzia Capelletti, A. John Iafrate, Charles Lee, James G. Christensen, Jeffrey A. Engelman, Pasi A. Jänne

    Cyhoeddwyd 2010
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

    Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models gan Ryan B. Corcoran, Katherine A. Cheng, Aaron N. Hata, Anthony C. Faber, Hiromichi Ebi, Erin M. Coffee, Patricia Greninger, Ronald D. Brown, Jason Godfrey, Travis J. Cohoon, Youngchul Song, Eugene Lifshits, Kenneth E. Hung, Toshi Shioda, Dora Dias‐Santagata, Anurag Singh, Jeffrey Settleman, Cyril H. Benes, Mari Mino‐Kenudson, Kwok‐Kin Wong, Jeffrey A. Engelman

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <i>KRAS</i> or <i>BRAF</i> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

    mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <i>KRAS</i> or <i>BRAF</i> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 gan Anthony C. Faber, Erin M. Coffee, Carlotta Costa, Anahita Dastur, Hiromichi Ebi, Aaron N. Hata, Alan T. Yeo, Elena J. Edelman, Youngchul Song, Ah Ting Tam, Jessica L. Boisvert, Randy Milano, Jatin Roper, David P. Kodack, Rakesh K. Jain, Ryan B. Corcoran, Miguel N. Rivera, Sridhar Ramaswamy, Kenneth E. Hung, Cyril H. Benes, Jeffrey A. Engelman

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Activation of PI3K Signaling in Merkel Cell Carcinoma

    Activation of PI3K Signaling in Merkel Cell Carcinoma gan Valentina Nardi, Youngchul Song, Juan A. Santamaria‐Barria, Arjola K. Cosper, Quynh Lam, Anthony C. Faber, Genevieve M. Boland, Beow Y. Yeap, Kristin Bergethon, Vanessa Scialabba, Hensin Tsao, Jeffrey Settleman, David P. Ryan, Darrell R. Borger, Atul K. Bhan, Mai P. Hoang, A. John Iafrate, James C. Cusack, Jeffrey A. Engelman, Dora Dias‐Santagata

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors

    BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors gan Anthony C. Faber, Ryan B. Corcoran, Hiromichi Ebi, Lecia V. Sequist, Belinda A. Waltman, Euiheon Chung, João Incio, Subba R. Digumarthy, Sarah F. Pollack, Youngchul Song, Alona Muzikansky, Eugene Lifshits, Sylvie Roberge, Erik J. Coffman, Cyril H. Benes, Henry Gómez, José Baselga, Carlos L. Arteaga, Miguel N. Rivera, Dora Dias‐Santagata, Rakesh K. Jain, Jeffrey A. Engelman

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

    The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models gan Sen Zhang, Rana Anjum, Rachel M. Squillace, Sara Nadworny, Tianjun Zhou, Jeff Keats, Yaoyu Ning, Scott Wardwell, David F. Miller, Youngchul Song, Lindsey Eichinger, Lauren Moran, Wei‐Sheng Huang, Shuangying Liu, Dong Zou, Yihan Wang, Qurish K. Mohemmad, Hyun Gyung Jang, Emily Ye, Narayana I. Narasimhan, Frank Wang, Juan J. Miret, Xiaotian Zhu, Tim Clackson, David C. Dalgarno, William C. Shakespeare, Victor M. Rivera

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

    Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer gan Anthony C. Faber, Anna F. Farago, Carlotta Costa, Anahita Dastur, María Gomez‐Caraballo, Rebecca Robbins, Bethany L. Wagner, William M. Rideout, Charles T. Jakubik, Jungoh Ham, Elena J. Edelman, Hiromichi Ebi, Alan T. Yeo, Aaron N. Hata, Youngchul Song, Neha U. Patel, Ryan J. March, Ah Ting Tam, Randy Milano, Jessica L. Boisvert, Mark Hicks, Sarah Elmiligy, Scott Malstrom, Miguel N. Rivera, Hisashi Harada, Brad E. Windle, Sridhar Ramaswamy, Cyril H. Benes, Tyler Jacks, Jeffrey A. Engelman

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: